The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1327
Ophthalmic Besifloxacin (Besivance)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the fluoroquinolone besifloxacin 0.6% ophthalmic suspension (Besivance – Bausch & Lomb) for treatment of bacterial conjunctivitis caused by susceptible bacteria. According to the manufacturer, this product was developed specifically for ophthalmic use in a specialized vehicle designed to prolong contact time on the ocular surface. Besifloxacin is not available for systemic use.

OTHER OPHTHALMIC ANTIBACTERIALS — Ophthalmic formulations of antibacterial drugs achieve high concentrations on the surface of the eye and may be effective clinically even when organisms are reported to be resistant in vitro.

Sulfacetamide is widely used, but can cause contact sensitivity reactions and rarely has caused Stevens- Johnson syndrome. Neomycin also causes sensitization and other local reactions in about 5-10% of patients. Chloramphenicol ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ophthalmic Besifloxacin (Besivance)
Article code: 1327e
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian